- Home
- UHG vs SLS Comparison
UHG vs SLS Comparison
Compare UHG & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UHG | SLS |
|---|---|---|
| Founded | 2004 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 248.7M | 208.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | UHG | SLS |
|---|---|---|
| Price | $1.68 | $4.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 244.4K | ★ 13.8M |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $418,113,017.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.99 | $0.85 |
| 52 Week High | $4.81 | $5.18 |
Technical Indicators
Market Signals| Indicator | UHG | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 57.17 | 64.75 |
| Support Level | $1.57 | $3.23 |
| Resistance Level | $1.81 | $4.33 |
| Average True Range (ATR) | 0.16 | 0.61 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 70.04 | 59.97 |
Price Performance
Historical ComparisonAbout UHG United Homes Group Inc
United Homes Group Inc operates as a homebuilder which operates with a land-light idea in the Southeast. The company currently has a presence in South Carolina, North Carolina, and Georgia and focuses on providing high-quality, affordable homes for the entry-level and first-move-up segments. The company has three reportable segments: GSH South Carolina, Rosewood, and Other.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.